Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

Inclusion Criteria

• •1. Signed informed consent in the local language prior to any study-mandated procedure.
• •2. Male or female patients at least 18 years of age, at the time of informed consent.
• •3. Male or nonpregnant and nonlactating female patients with pathologically confirmed, measurable solid tumor lesions (Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\]) that are unresectable, and standard therapy able to provide clinical benefit does not exist or is no longer effective.
• •4. Eastern Cooperative Oncology Group Performance Status ≤2.
• •5. Patients have recovered from the acute toxicity of previous therapies (peripheral sensory neuropathy recovered to ≤Grade 2) except alopecia, and:
• •* At least 4 weeks have elapsed since completing surgery, endocrine therapy, tyrosine kinase inhibitor therapy, immunotherapy, radiotherapy, chemotherapy, and/or
• •* At least 6 weeks have elapsed since completing chemotherapy with nitrosoureas, melphalan, and/or mitomycin C, and/or
• •* At least 6 weeks have elapsed since completing cranial radiotherapy.
• •6. Life expectancy of greater than 12 weeks.
• •7. Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.